[Comment] Daratumumab maintenance in patients with myeloma

High-dose melphalan followed by autologous haematopoietic stem-cell transplantation (ASCT) has been the standard of care in myeloma treatment for the past three decades, however, the curative success rate is low and quadruplet regimens are gaining acceptance.1 In view of the high response rates observed with daratumumab, anti-CD38 monoclonal antibodies have been added to the backbone of induction regimens. The figure (appendix) summarises the progression-free survival results of induction regimens tested in previous studies.